FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Tags >> FDA   Phase III   Novartis   GlaxoSmithKline
Syndicate content

priority News

Most Popular priority Story

Prasugrel gets priority review

The FDA has granted priority review to Eli Lilly and Daiichi Sankyo's prasugrel, an anti-clotting drug. The NDA for prasugrel was submitted to the agency in December. Now the drugmakers can expect an Read more...

Latest Headlines